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Introduction
The basic helix-loop-helix (bHLH) proteins are comprised of several proteins that function as transcription factors and play a regulatory role in several biochemical and physiological processes-differentiation, proliferation/cell-cycle arrest and survival/apoptosis. It was studies on neuronal cells that led to the cloning of two Hairy and Enhancer of Split (HES) proteins in 1992 [1] . There are presently seven Hes proteins (HES1-7) and they all exhibit homology at the amino-acid level of the bHLH domain [1] [2] [3] [4] [5] [6] [7] . The Hes superfamily has a common proline residue within its basic motif, and the highly conserved tetrapetide domain: Trp-Arg-Pro-Trp (WRPW) at the C-terminus. Additionally, there is an 'Orange Domain' which is comprised of approximately 35 amino acids and this motif is located proximal to the C-terminus of the bHLH domain. The Orange domain thus provides an interface for protein-protein interaction [8] . HES1 is comprised of a basic DNA binding domain, followed by the helix-loop-helix (HLH) domain for dimerization (homo/hetero), the 'Orange' domain, a proline rich region and the WRPW domain.
The bHLH domain of HES1 can form homo or hetero dimers with other members of the bHLH superfamily. HES1 binds to an N-box sequence (CACNAG) or a similar N-box sequence CACGCG (denoted as the class C site) present on the promoters of genes to regulate their expression. Widely recognised as a transcriptional repressor, HES1 mediates its actions by a feedback negative loop, regulating its own expression through a tetrameric Nbox site located within its promoter, to which it binds (Figure 1 ). Another suggested mechanism of transcriptional repression, is through the WRPW motif present at the Cterminus [9] . Here, the transducin-like enhancer of split (TLE), which is a corepressor, interacts with the WRPW motif of HES1 and leads to the recruitment of histone deacetylases (HDAC) onto the promoters of the HES1 bound target genes. This results in repression of the target genes [10, 11] .
Although well known as a transcriptional repressor of the NOTCH signalling pathway, HES1 also functions as a transcriptional activator of some genes/targets and its dual role may be dependent on the interacting proteins that form the HES1 transcriptional complex. Its activating potential has been demonstrated upon stimulation with the epidermal growth factor (EGF) where HES1 upon binding to STAT3, leads to an enhancement in gene expression [12] . Interaction between HES1 and Runt-related transcription factor 2 (Runx2) leads to an enhancement in the transcriptional activity of Runx2, inspite of HES1 being a repressor.
HES1 also induces activation of PARP1 in B-cell acute lymphoblastic leukaemia (ALL) to induce apoptosis and tumor suppressive activity [13] . Thus, HES1 may function as either repressors or activators depending on the transcriptional complexes and thereby establishing a potential mechanism of cell specific dependent regulation. 
Regulation of HES1
HES1 is activated by both canonical and non-canonical pathways and NOTCH represents one of the prominent canonical pathways. Signalling mediated by the NOTCH pathway plays an important role in cellular functions such as proliferation, differentiation, survival and apoptosis [14] . NOTCH plays complex opposing roles depending on the cellular context: in mammary adenocarcinoma and T-cell acute lymphoblastic leukaemia (ALL) it functions as an oncogene whereas, in contrast, it acts as a tumour suppressor in B cell and neuroendocrine malignancies ( [15] [16] [17] [18] . Upon binding of the ligand (Jagged 1, 2, and Delta-like (Dll) 1, 3, 4) to the NOTCH receptor, there is a cascade of events which results in the exposure of cleaving sites for ADAM 10 and Y secretase resulting in the release of the intracellular domain of the NOTCH receptor (NICD). The NICD, then translocates within the nucleus and binds to transcription factors, primarily RBPjk, which leads to recruitment of co-activators/corepressors that results in the transcription of target genes, including HES1.
The hedgehog pathway represents another mode of HES1 induction [19] . It was global gene expression studies using microarray in multipotent mesodermal cells that demonstrated the bHLH Proline rich region
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Orange WRPW regulation of HES1 by overexpressing sonic hedgehog [19] . This was validated using the NOTCH pathway inhibitor DAPT and chromatin immunoprecipitation studies on Gli1 targets [20] . 
Role in immunity
A crucial target of the NOTCH signalling pathway, HES1, is expressed in hematopoietic cells and thymic stroma and plays an important role in the development of T cells. This was confirmed in HES1 knockout mice, where 90% of HES1 deficient embryos presented with no thymus and <10% presented with an undeveloped thymus and here T cell development was blocked at the double negative stage (TCRβ-and TCRγδ-) [24] . A previous study in Rag1 deficient mice had demonstrated that fetal liver cells deficient in HES1 had a defective reconstitution of T cells and a culture of the fetal thymus showed that there was a decrease in the cellularity in the lobes deficient in HES1 [25] . Again, a deletion of HES1 in the bone marrow progenitor cells, resulted in a reduction (80%) in thymic cellularity [26] . HES1 deficient progenitor cells led to thymocyte differentiation being arrested at the early stages of clonal diversity, leading to a reduction in thymocyte numbers. Interestingly, NOTCH deficient mice, showed similar effects on thymocyte differentiation, leading to the notion that early stage hematopoietic cell differentiation was dependent on NOTCH mediated regulation of HES1 [27] . Kunisato et al, using alternative models reported that hematopoietic stem cell expansion could be maintained by upregulating HES1 [28] . One of the possible mechanisms by which HES1 promotes hematopoietic stem cell differentiation, is by suppressing Cdkn1b, which encodes the cell-cycle inhibitor p27 Kip1 [29] . A recent study by Wong et al confirmed the role of NOTCH induced HES1 and its regulation of PTEN (phosphatase and tensin homolog), a PI3K/Akt inhibitor, during normal T cell development [30] . In colon cancer, HES1 was found to be upregulated in poorly differentiated cancer samples when compared to well-differentiated tumour samples. Again, the expression level of HES1 positively correlated with the level of CD133 in colon cancer samples and an increase in HES1 expression lead to a concomitant increase in the number of CD133 positive cells [36] .
A previous study using lentiviral delivery of human CD133 into the rat C6 glioma cells (hCD133-C6) to produce genetically modified cell lines of rat glioma, were used to study the role of CD133 in tumorigenicity. Here, NOTCH activation and an upregulation of HES1 was observed in C6 cells that were stably expressing hCD133. Downregulating HES1 expression, using shRNA mediated knockdown, led to a reduction in the colony forming ability of the hCD133-C6 cells. It was inferred from these studies that stably expressing hCD133 via activation of NOTCH, resulted in cell proliferation of C6 cells. This was reflected in-vivo, where tumour formation and progression was pronounced in the hCD133-C6 cells when compared to the untransfected C6 cells [41] . The importance of the NOTCH-HES1 axis was also studied in pancreatic cancer with similar observations [42] . An association of the NOTCH/HES1 role has also been reported in breast cancer and that there is an upregulation of the NOTCH receptors in breast cancer cells when compared to normal epithelia in the breast [43] . Cells expressing high CD44 but negatively stained for CD24 (CD44 + /CD24 −/low cells), were resistant to chemotherapy and were most commonly found in basal-like breast tumours and had a high frequency of early relapse [44] . Moreover, activation of the NOTCH pathway is essential in the maintenance of CD44 + /CD24 −/low cancer stem cells in breast cancer [45] . A recent study showed that addition of BXL0124 (Gemin Vitamin D analog) led to a reduction in the CD44 + /CD24 −/low tumour initiating cells and it was confirmed that the NOTCH-HES1 axis was inhibited by BXL0124 and a subsequent reduction in the CD44 + /CD24 −/low cells in basal-like breast cancer.
HES1 is involved in the tumorigenicity of stem cells in colon cancer [36] . HES1 is upregulated in metastatic prostate cancer cells, PC3 and PC3M. With the crucial role played by HES1 in tumour invasion and metastasis, it is imperative to study its role in epithelialmesenchymal transition (EMT), since EMT is considered to be the mechanism that promotes invasion and metastasis. Phosphatase and tensin homolog (PTEN) plays a crucial role in the regulation of EMT during embryogenesis and progression of cancer by downregulating the PI3K/AKT pathway [46] . Increasing evidence supports that inactivation or downregulation of the tumor suppressor PTEN triggers EMT in cancer, thereby promoting invasion and metastasis [47] . A recent study has demonstrated that HES1 promotes EMT related alterations by activating the AKT/PTEN axis in nasopharyngeal carcinoma (NPC) [48] .
Again, HES1 has also been implicated in promoting cancer cell transformation and resistance to therapy (chemo/endocrine). One of the possible mechanisms of resistance to chemotherapy is through an upregulation of HES1, accompanied by an increase in STAT3 phosphorylation and activity [12] .
HES1 is understood to promote cell proliferation by regulating factors involved in the cell cycle for example p21, p27 and CDK inhibitors of G1-S phase [29] . HES1 maintains cell quiescence by inhibiting p21 and thus preventing senescence [49] . Further mechanism is by repressing the CDK inhibitor, CDKN1C/P57, involved in cell cycle arrest at the G1 phase, thereby hindering p57 mediated senescence [50] . Thus, HES1 promotes and maintains malignancy through several mechanisms with a central role played by the NOTCH-HES1
axis.
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